The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice. METHODS: We enrolled a total of 1540 patients in three prospective trials of intensive therapy. Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, we defined AML genomic subgroups and their relevance to clinical outcomes. RESULTS: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients. Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clinical outcomes. In addition to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2(R172) mutations (in 1%). Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome. In addition to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival. The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations. Such gene-gene interactions were especially pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis. These predictions require validation in prospective clinical trials. CONCLUSIONS: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Papaemmanuil et al. 2016
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Leukemia is frequently driven by mutations in epigenetic modifiers or signaling master regulators58 that lead to gross alterations of the epigenetic landscape59 and an epigenetic environment widely permissive of activation.”
From Design principles of cell-state-specific enhancers in hematopoiesis (2025) · cites this paper as [58]
In the citing paper
“Particularly in acute myeloid leukemia (AML), a prominent component of the disease is recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events (14)(15)(16)(17).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [16]
In the citing paper
“We identified 391 out of the 622 curated COSMIC cancer-related and AML-related genes located inside the altered TADs in at least one sample, and more than 100 are recurrent across multiple samples (Extended Data Fig. 3b)4,24,25.”
From Subtype-specific 3D genome alteration in acute myeloid leukaemia (2022) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationGrimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,031
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,007
Emerging therapies for acute myeloid leukemia: translating biology into the clinic
Kavanagh, S., Murphy, T., Law, A., Yehudai, D., Ho, J., Chan, S., & Schimmer, A. D. (2017) · JCI Insight · doi:10.1172/jci.insight.95679 · Cited by 37
Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition
Moison, C., Lavallée, V., Thiollier, C., Lehnertz, B., Boivin, I., Mayotte, N., Gareau, Y., Fréchette, M., Blouin-Chagnon, V., Corneau, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028480 · Cited by 35
van Dijk, A. D., de Bont, E. S. J. M., & Kornblau, S. M. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1717951 · Cited by 34
Röhnert, M. A., Krämer, M., Schadt, J., Ensel, P., Thiede, C., Krause, S. W., Bücklein, V., Hoffmann, J., Jaramillo, S., Schlenk, R. F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01647-5 · Cited by 34
Self-citationSeverens, J. F., Karakaslar, E. O., van der Reijden, B. A., Sánchez‐López, E., van den Berg, R. R., Halkes, C. J. M., van Balen, P., Veelken, H., Reinders, M. J. T., Griffioen, M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02137-6 · Cited by 34
Schwede, M., Jahn, K., Kuipers, J., Miles, L. A., Bowman, R. L., Robinson, T. M., Furudate, K., Uryu, H., Tanaka, T. N., Sasaki, Y., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02211-z · Cited by 34
Larrue, C., Mouche, S., Angelino, P., Sajot, M., Birsen, R., Kosmider, O., McKee, T., Vergez, F., Récher, C., Mas, V. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1731 · Cited by 35
Functions of the native NPM1 protein and its leukemic mutant
Falini, B., Sorcini, D., Perriello, V. M., & Sportoletti, P. (2024) · Leukemia · doi:10.1038/s41375-024-02476-4 · Cited by 36
Lee, J., Salci, K. R., Reid, J. C., Orlando, L., Tanasijevic, B., Shapovalova, Z., & Bhatia, M. (2017) · Stem Cells · doi:10.1002/stem.2655 · Cited by 37
Schneidawind, C., Jeong, J., Schneidawind, D., Kim, I., Duque‐Afonso, J., Wong, S. H. K., 岩崎, 正., Breese, E. H., Zehnder, J. L., Porteus, M. H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017013748 · Cited by 37
When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Roloff, G. W., & Griffiths, E. A. (2018) · Hematology · doi:10.1182/asheducation-2018.1.35 · Cited by 34
Dissecting the Immune Landscape of Acute Myeloid Leukemia
Davidson-Moncada, J. K., Viboch, E., Church, S., Warren, S. E., & Rutella, S. (2018) · Biomedicines · doi:10.3390/biomedicines6040110 · Cited by 34
The Regulatory Roles of Long Noncoding RNAs in Acute Myeloid Leukemia
Ng, M. S. W., Heckl, D., & Klusmann, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00570 · Cited by 34
Möröy, T., & Khandanpour, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00824 · Cited by 34
Barth, B. M., Wang, W., Toran, P. T., Fox, T. E., Annageldiyev, C., Ondrasik, R. M., Keasey, N. R., Brown, T. J., Devine, V., Sullivan, E. C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018021295 · Cited by 34
Glüxam, T., Grandits, A. M., Schlerka, A., Nguyen, C. H., Etzler, J., Finkes, T., Fuchs, M., Scheid, C., Heller, G., Hackl, H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235826 · Cited by 35
Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML
Li, S., Chen, X., Wang, J., Meydan, C., Glass, J. L., Shih, A. H., Delwel, R., Levine, R. L., Mason, C. E., & Melnick, A. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0897 · Cited by 35
Todisco, G., Creignou, M., Gallì, A., Guglielmelli, P., Rumi, E., Roncador, M., Rizzo, E., Nannya, Y., Pietra, D., Elena, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01106-z · Cited by 35
Massett, M. E., Monaghan, L., Patterson, S. D., Mannion, N., Bunschoten, R. P., Hoose, A., Marmiroli, S., Liskamp, R. M. J., Jørgensen, H. G., Vetrie, D. L. P., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03738-0 · Cited by 34
Wang, R., Zheng, X., Wang, J., Wan, S., Song, F., Wong, M. H., Leung, K. S., & Cheng, L. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac002 · Cited by 34
Application of precision medicine in clinical routine in haematology—Challenges and opportunities
Wästerlid, T., Cavelier, L. B., Haferlach, C., Konopleva, M. Y., Fröhling, S., Östling, P., Bullinger, L., Fioretos, T., & Smedby, K. E. E. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13508 · Cited by 35
Self-citationZhu, Y., Liu, Z., Wan, Y., Zou, L., Liu, L., Ding, S., Chen, L., & Qiu, F. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109094 · Cited by 36
The Wnt/β-catenin signalling pathway in Haematological Neoplasms
Yu, S., Han, R., & Gan, R. (2022) · Biomarker Research · doi:10.1186/s40364-022-00418-9 · Cited by 38
Maggioni, G., Bersanelli, M., Travaglino, E., Piérola, A. A., Kasprzak, A., Montserrat, A. S., Sauta, E., Sala, C., Matteuzzi, T., Meggendorfer, M., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00323-4 · Cited by 34
Perriello, V. M., Rotiroti, M. C., Pisani, I., Galimberti, S., Alberti, G., Pianigiani, G., Ciaurro, V., Marra, A., Sabino, M., Tini, V., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008762 · Cited by 34
Pastoret, C., Houot, R., Llamas‐Gutierrez, F., Boulland, M., Marchand, T., Tas, P., Sunnaram, B. L., Gandemer, V., Lamy, T., Roussel, M., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1225208 · Cited by 35
Thomas, M., Sukhai, M. A., Zhang, T., Dolatshahi, R., Harbi, D., Garg, S., Misyura, M., Pugh, T. J., Stockley, T. L., & Kamel‐Reid, S. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0547-ra · Cited by 34
Weinberg, O. K., Gibson, C. J., Blonquist, T. M., Neuberg, D. S., Pozdnyakova, O., Kuo, F. C., Ebert, B. L., & Hasserjian, R. P. (2018) · Haematologica · doi:10.3324/haematol.2017.181842 · Cited by 34
Brunner, A. M., Neuberg, D. S., Wander, S. A., Sadrzadeh, H., Ballen, K. K., Amrein, P. C., Attar, E. C., Hobbs, G. S., Chen, Y., Perry, A. M., et al. (2018) · Cancer · doi:10.1002/cncr.31729 · Cited by 35
Tsai, C., Yao, C., Tien, F., Tang, J., Kuo, Y., Chiu, Y., Lin, C., Tseng, M., Peng, Y., Liu, M.-C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.022 · Cited by 35
Mitchell, K., & Steidl, U. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036251 · Cited by 37
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Zavras, P. D., Sinanidis, I., Tsakiroglou, P., & Karantanos, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055018 · Cited by 33
Novel Tools for Diagnosis and Monitoring of AML
Guijarro, F., Garrote, M., Villamor, N., Colomer, D., Esteve, J., & López‐Guerra, M. (2023) · Current Oncology · doi:10.3390/curroncol30060395 · Cited by 33
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 33
Pellagatti, A., & Boultwood, J. (2016) · Advances in Biological Regulation · doi:10.1016/j.jbior.2016.08.001 · Cited by 34
Almeida, A. M., Prébet, T., Itzykson, R., Ramos, F., Al‐Ali, H. K., Shammo, J. M., Pinto, R., Maurillo, L., Wetzel, J. L., Musto, P., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040837 · Cited by 33
ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics
Kakosaiou, K., Panitsas, F. P., Daraki, A., Pagoni, M. N., Apostolou, P., Ioannidou, A., Vlachadami, I., Marinakis, T. P., Giatra, C., Vasilatou, D., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1433298 · Cited by 33
Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics
Alonso, C. M., Llop, M., Sargas, C., Pedrola, L., Panadero, J., Hervás, D., Cervera, J., Such, E., Ibáñez, M., Ayala, R. M., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.09.009 · Cited by 33
Lima, K., Coelho‐Silva, J. L., Kinker, G. S., Pereira‐Martins, D. A., Traina, F., Fernandes, P. A. C. M., Markus, R. P., Lucena-Araujo, A. R., & Machado‐Neto, J. A. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.04.002 · Cited by 34
Xuan, L., Wang, Y., Chen, J., Jiang, E., Gao, L., Wu, B., Deng, L., Liang, X., Huang, F., Fan, Z., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.04.018 · Cited by 33
Jeong, J., Jager, A., Domizi, P., Pavel-Dinu, M., Gojenola, L., 岩崎, 正., Wei, M. C., Pan, F., Zehnder, J. L., Porteus, M. H., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000450 · Cited by 35
Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis
Zhou, T., Bloomquist, M. S., Ferguson, L. S., Reuther, J., Marcogliese, A. N., Elghetany, M. T., Roy, A., Rao, P. H., Lopez-Terrada, D. H., Redell, M. S., et al. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1683107 · Cited by 33
Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joining
Feldman, T., Bercovich, A., Moskovitz, Y., Chapal-Ilani, N., Mitchell, A., Medeiros, J. J. F., Biezuner, T., Kaushansky, N., Minden, M. D., Gupta, V. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22803-y · Cited by 34
Chromosomal Instability in Acute Myeloid Leukemia
Lisboa, M. D. O., Brofman, P. R. S., Schmid-Braz, A. T., Pozzo, A. R., & Mai, S. (2021) · Cancers · doi:10.3390/cancers13112655 · Cited by 33
SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade
Volpe, V. O., Garcia‐Manero, G., & Komrokji, R. S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.031 · Cited by 33
Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia
Petti, A. A., Khan, S. M., Xu, Z., Helton, N., Fronick, C. C., Fulton, R., Ramakrishnan, S. M., Srivatsan, S. N., Heath, S. E., Westervelt, P., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0050 · Cited by 35
The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia
Moser, B., Edtmayer, S., Witalisz‐Siepracka, A., & Stoiber, D. (2021) · Biomedicines · doi:10.3390/biomedicines9081051 · Cited by 35
Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia
Lilljebjörn, H., Orsmark‐Pietras, C., Mitelman, F., Andersson, A., & Fioretos, T. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.013 · Cited by 33
Porazzi, P., Petruk, S., Pagliaroli, L., Dominici, M. D., Deming, D., Puccetti, M. V., Kushinsky, S., Kumar, G., Minieri, V., Barbieri, E., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1297 · Cited by 35
Oncogenic and Tumor-Suppressive Functions of the RNA Demethylase FTO
Zuidhof, H. R., & Calkhoven, C. F. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3710 · Cited by 33
Recent advances of nanodrug delivery system in the treatment of hematologic malignancies
Ye, Q.-L., Lin, Y. H., Li, R., Wang, H., & Dong, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.016 · Cited by 33
New Therapeutic Strategies for Adult Acute Myeloid Leukemia
Ishii, H., & Yano, S. (2022) · Cancers · doi:10.3390/cancers14112806 · Cited by 33
Vergez, F., Largeaud, L., Bertoli, S., Nicolau-Travers, M.-L., Rieu, J., Vergnolle, I., Saland, E., Sarry, A., Tavitian, S., Huguet, F., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00712-7 · Cited by 36
Sargas, C., Ayala, R. M., Larráyoz, M. J., Chillón, C., Carrillo‐Cruz, E., Bilbao, C., de la Torre, E. P., Martínez‐Cuadrón, D., Rodríguez‐Veiga, R., Boluda, B., et al. (2023) · Cancers · doi:10.3390/cancers15020438 · Cited by 33
Zhu, Y., Wang, P., Huang, J.-Y., Chen, Y., Chen, B., Dai, Y., Han, Y. Y., Hu, Y., Cheng, W., Ma, T., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1279-4 · Cited by 34
Molecular pathogenesis of disease progression in MLL-rearranged AML
Kotani, S., Yoda, A., Kon, A., Kataoka, K., Ochi, Y., Shiozawa, Y., Hirsch, C. M., Takeda, J., Ueno, H., Yoshizato, T., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0253-3 · Cited by 34
Wu, D., Luo, X., Feurstein, S. K., Kesserwan, C. A., Mohan, S., Álvarez, D. E. P., & Godley, L. A. (2020) · Haematologica · doi:10.3324/haematol.2018.214221 · Cited by 33
Jin, P., Tan, Y., Zhang, W., Li, J., & Wang, K. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.004 · Cited by 33
Ex-vivo drug testing predicts chemosensitivity in acute myeloid leukemia
Lin, L., Tong, Y., Straube, J., Zhao, J., Gao, Y., Bai, P., Li, J., Wang, J., Wang, H., Wang, X., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5a0220-676rr · Cited by 32
Kumana, C. R., Mak, R., Kwong, Y., & Gill, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01294 · Cited by 32
Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
Wei, W., Huang, S., Ling, Q. D., Mao, S., Yu, Q., Ye, W., Li, F., Pan, J., Lin, X., Huang, J., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03497-2 · Cited by 32
Genetics and pathologic landscape of lineage switch of acute leukemia during therapy
Zhou, T., Curry, C. V., Khanlari, M., Shi, M., Cui, W., Peker, D., Chen, W., Wang, E., Gao, J., Shen, Q., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00983-2 · Cited by 32
Shimony, S. O., Garcia, J. S., Keating, J. H., Chen, E. C., Luskin, M. R., Stahl, M. F., Neuberg, D. S., DeAngelo, D. J., Stone, R. M., & Lindsley, R. C. (2024) · Leukemia · doi:10.1038/s41375-024-02230-w · Cited by 32
Fischer, A. H., Hernández-Rodríguez, B., Mulet‐Lazaro, R., Nuetzel, M., Hölzl, F., van Herk, S., Kavelaars, F. G., Stanewsky, H., Ackermann, U., Niang, A. H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114498 · Cited by 32
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Senapati, J., Kadia, T. M., Daver, N. G., Dinardo, C. D., Borthakur, G. M., Ravandi, F., & Kantarjian, H. M. (2025) · Cancer · doi:10.1002/cncr.35806 · Cited by 32
IRF2–INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells
Zhang, F., Li, J., Zhu, J., Liu, L., Zhu, K., Cheng, S., Lv, R., & Zhang, P. (2019) · Biological Research · doi:10.1186/s40659-019-0218-7 · Cited by 32
Patel, S. S., Pinkus, G. S., Ritterhouse, L. L., Segal, J. P., Cin, P. D., Restrepo, T., Harris, M. H., Stone, R. M., Hasserjian, R. P., & Weinberg, O. K. (2019) · American Journal of Hematology · doi:10.1002/ajh.25544 · Cited by 33
Transcriptional networks in acute myeloid leukemia
Thoms, J. A. I., Beck, D., & Pimanda, J. E. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22794 · Cited by 33
A Critical Review of Animal Models Used in Acute Myeloid Leukemia Pathophysiology
Skayneh, H., Jishi, B., Hleihel, R., Hamieh, M., Darwiche, N., Bazarbachi, A. A., El-Sabban, M. E., & Hajj, H. E. (2019) · Genes · doi:10.3390/genes10080614 · Cited by 32
Sakaguchi, M., Yamaguchi, H., Kuboyama, M., Najima, Y., Usuki, K., Ueki, T., Oh, I., Mori, S., Kawata, E., Uoshima, N., et al. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02720-z · Cited by 32
AML through the prism of molecular genetics
Charrot, S., Armes, H., Rio‐Machín, A., & Fitzgibbon, J. (2019) · British Journal of Haematology · doi:10.1111/bjh.16356 · Cited by 33
Supper, E., Rudat, S., Iyer, V., Droop, A., Wong, K., Spinella, J.-F., Thomas, P., Sauvageau, G., Adams, D. J., & Wong, C. C. (2021) · Nature Communications · doi:10.1038/s41467-021-22750-8 · Cited by 33
Zhou, H., Liu, W., Zhou, Y., Hong, Z., Ni, J., Zhang, X., Li, Z., Li, M., He, W., Zhang, D., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02145-9 · Cited by 32
Li, Y., Peng, H., Jiang, P., Zhang, J., Zhao, Y., Feng, X., Pang, C., Ren, J., Zhang, H., Bai, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.824258 · Cited by 32
Timmerman, D. M., Eleveld, T. F., Sriram, S., Dorssers, L. C. J., Gillis, A., Schmidtova, S., Kaľavská, K., van de Werken, H. J. G., Oing, C., Honecker, F. U., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02809 · Cited by 32
Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies
Fukuhara, S., Oshikawa‐Kumade, Y., Kogure, Y., Shingaki, S., Kariyazono, H., Kikukawa, Y., Koya, J., Saito, Y., Tabata, M., Yoshifuji, K., et al. (2022) · Cancer Science · doi:10.1111/cas.15427 · Cited by 32
Gallazzi, M., Ucciero, M. A. M., Faraci, D., Mahmoud, A. M., Essa, W. A., Gaïdano, G., Mouhssine, S., & Crisà, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147542 · Cited by 32
Control of ribosomal RNA synthesis by hematopoietic transcription factors
Charles Antony, A., George, S. S., Blum, J., Somers, P., Thorsheim, C. L., Wu-Corts, D. J., Ai, Y., Gao, L., Lv, K., Tremblay, M. G., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.08.027 · Cited by 32
Rivera, D., Kim, K., Kanagal‐Shamanna, R., Borthakur, G. M., Bravo, G. M., Daver, N. G., Dinardo, C. D., Short, N. J., Yilmaz, M. E., Pemmaraju, N., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26731 · Cited by 32
Contribution of metabolic abnormalities to acute myeloid leukemia pathogenesis
Egan, G., & Schimmer, A. D. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.11.004 · Cited by 35
Early response evaluation by single cell signaling profiling in acute myeloid leukemia
Tislevoll, B. S., Hellesøy, M., Fagerholt, O. H. E., Gullaksen, S., Srivastava, A., Birkeland, E., Kleftogiannis, D., Durán, P. A., Piechaczyk, L., Tadele, D. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35624-4 · Cited by 33
Casado, P., Rio‐Machín, A., Miettinen, J. J., Bewicke‐Copley, F., Rouault‐Pierre, K., Krizsán, S., Parsons, A., Rajeeve, V., Miraki‐Moud, F., Taussig, D. C., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01288-1 · Cited by 32
How do messenger RNA splicing alterations drive myelodysplasia?
Joshi, P. M., Halene, S., & Abdel-Wahab, O. I. (2017) · Blood · doi:10.1182/blood-2017-02-692715 · Cited by 35
Shepherd, M. S., Li, J., Wilson, N. K., Oedekoven, C. A., Li, J., Belmonte, M., Fink, J., Prick, J. C. M., Pask, D. C., Hamilton, T. L., et al. (2018) · Blood · doi:10.1182/blood-2017-12-821066 · Cited by 33
Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia
Izaguirre-Carbonell, J., Christiansen, L., Burns, R., Schmitz, J., Li, C., Mokry, R. L., Bluemn, T., Zheng, Y., Shen, J., Carlson, K.-S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026054 · Cited by 33
Zhang, C., Lam, S. S. Y., Leung, G. M. K., Tsui, S. P., Yang, N., Ng, N. K. L., Ip, H., Au, C. H., Chan, T., Ma, E. S. K., et al. (2019) · Cancer · doi:10.1002/cncr.32534 · Cited by 32
Resistance to targeted therapies in acute myeloid leukemia
Mecklenbrauck, R., & Heuser, M. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10189-0 · Cited by 31
Self-citationLandscape of driver mutations and their clinical effects on Down syndrome–related myeloid neoplasms
Sato, T., Yoshida, K., Toki, T., Kanezaki, R., Terui, K., Saiki, R., Ojima, M., Ochi, Y., Mizuno, S., Yoshihara, M., et al. (2024) · Blood · doi:10.1182/blood.2023022247 · Cited by 31
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Carosi, F., Broseghini, E., Fabbri, L., Corradi, G., Gili, R., Forte, V., Roncarati, R., Filippini, D. M., & Ferracin, M. (2024) · Cancers · doi:10.3390/cancers16152752 · Cited by 31
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
Kats, L. M., Vervoort, S. J., Cole, R., Rogers, A. J., Gregory, G. P., Vidacs, E., Li, J., Nagaraja, R., Yen, K. E., & Johnstone, R. W. (2017) · Leukemia · doi:10.1038/leu.2017.84 · Cited by 31
Xu, Y., Li, Y., Xu, Q., Chen, Y., Jing, Y., Jing, Y., Dou, L., Bo, J., Hou, G., Guo, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19628 · Cited by 32
Bapat, A., Keita, N., Martelly, W., Kang, P. T., Seet, C. S., Jacobsen, J. R., Stoilov, P., Hu, C., Crooks, G. M., & Sharma, S. (2018) · Stem Cells · doi:10.1002/stem.2885 · Cited by 31
A decade with whole exome sequencing in haematology
Hansen, M. H., Haferlach, T., & Nyvold, C. G. (2019) · British Journal of Haematology · doi:10.1111/bjh.16249 · Cited by 32
Optimal therapeutic strategies for mixed phenotype acute leukemia
Wolach, O., & Stone, R. M. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000570 · Cited by 31
Genua, C. D., Valletta, S., Buono, M., Stoilova, B., Sweeney, C., Rodríguez-Meira, A., Grover, A., Drissen, R., Meng, Y., Beveridge, R. D. D., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.022 · Cited by 34
Wu, H., Zhao, H., & Chen, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01253 · Cited by 31
IL2RA Promotes Aggressiveness and Stem Cell–Related Properties of Acute Myeloid Leukemia
Nguyen, C. H., Schlerka, A., Grandits, A. M., Koller, E., van der Kouwe, E., Vassiliou, G. S., Staber, P. B., Heller, G., & Wieser, R. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0531 · Cited by 31
Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells
Russkamp, N. F., Myburgh, R., Kiefer, J. D., Neri, D., & Manz, M. G. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.01.003 · Cited by 32
Design principles of cell-state-specific enhancers in hematopoiesis
Frömel, R., Rühle, J., Bernal Martinez, A., Szu-Tu, C., Pacheco Pastor, F., Martinez-Corral, R., & Velten, L. (2025) · Cell · doi:10.1016/j.cell.2025.04.017 · Cited by 29
Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Heinemann, T., Kornauth, C., Severin, Y., Vladimer, G. I., Pemovska, T., Hadzijusufovic, E., Agis, H., Krauth, M.-T., Sperr, W. R., Valent, P., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0219 · Cited by 28
Metadata
- Authors
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D. R., Teague, J. W., Butler, A. P., Greaves, M. F., Ganser, A., Döhner, K., Schlenk, R. F., Döhner, H., & Campbell, P. J.
- Affiliations
- European Bioinformatics Institute (GB)
- Wellcome Sanger Institute (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2209-2221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4979995
- OpenAlex
- W2419140434
- Cited by
- 4,350
- References
- 40
- Citations by year
- 2026: 345 · 2025: 403 · 2024: 468 · 2023: 460 · 2022: 551 · 2021: 583 · 2020: 481 · 2019: 415 · 2018: 286 · 2017: 282 · 2016: 63
- FWCI
- 331.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Wellcome Trust (103858/Z/14/Z, 105104, 077012/Z/05/Z, 077012, 103858, 105104/Z/14/Z, WT088340MA)
- Francis Crick Institute (10202)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- acute myeloid leukemia, driver mutations, genomic subgroups, prognostic stratification, TP53 mutation, aneuploidy, NPM1 mutation, IDH2 mutation, gene-gene interaction, co-mutation patterns, overall survival, intensive treatment
- MeSH terms
- DNA Methyltransferase 3A, Nucleophosmin, Adult, DNA (Cytosine-5-)-Methyltransferases, DNA Mutational Analysis, Epistasis, Genetic, Genotype, Humans, Middle Aged, Mutation, Nuclear Proteins, Prognosis, Prospective Studies, RNA Splicing, Leukemia, Myeloid, Acute, Proportional Hazards Models, Survival Analysis, Intracellular Signaling Peptides and Proteins, Gene Fusion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
